Skip to main content
SpringerLink
Log in

Phase I Trials in Pancreatic Cancer

  • Chapter
  • First Online:
Translational Pancreatic Cancer Research

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

Abstract

For a long time, pancreatic ductal adenocarcinoma (PDAC) has been a largely neglected entity in clinical research. Only recently there has been a substantial increase in the number, but also the spectrum of clinical trials for the treatment of pancreatic cancer in different clinical settings. This is partly due to a better understanding of the molecular setup of pancreatic cancer and consequently the definition of subgroups that allow a more specific targeting.

In this chapter we will highlight recent trends in the very early phase of clinical trials in pancreatic cancer. There are substantial activities in targeting specific signaling pathways overexpressed or active in PDAC, the cell cycle, and DNA damage repair, but also the tumor microenvironment including the stromal compartment and the immune system. Given the still poor prognosis of pancreatic cancer, even rather novel approaches such as CAR-T cells are tried in pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harder J, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106:1033–8.

    Article  CAS  Google Scholar 

  2. Tan EH, et al. Phase 1b trial of ficlatuzumab, a humanized hepatocyte growth factor inhibitory monoclonal antibody, in combination with gefitinib in Asian patients with NSCLC. Clin Pharmacol Drug Dev. 2018;7:532–42.

    Article  CAS  Google Scholar 

  3. Shi S, et al. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci. 2012;101:1969–84.

    Article  CAS  Google Scholar 

  4. Lorens J, et al. Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC. J Clin Oncol. 2018;36:3078.

    Article  Google Scholar 

  5. Drilon A, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.

    Article  CAS  Google Scholar 

  6. Drilon A, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7:963–72.

    Article  CAS  Google Scholar 

  7. Bekasi S, Zalatnai A. Overexpression of glucocorticoid receptor in human pancreatic cancer and in xenografts. An immunohistochemical study. Pathol Oncol Res. 2009;15:561–6.

    Article  CAS  Google Scholar 

  8. Liu Y, et al. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines. Cell Death Dis. 2017;8:e3022.

    Article  CAS  Google Scholar 

  9. Kanteti R, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018;19:316–27.

    Article  CAS  Google Scholar 

  10. Jiang H, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22:851–60.

    Article  CAS  Google Scholar 

  11. Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J Biol Chem. 2015;290:5592–605.

    Article  CAS  Google Scholar 

  12. Domoto T, et al. Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107:1363–72.

    Article  CAS  Google Scholar 

  13. Erazo T, et al. The new antitumor drug ABTL0812 inhibits the Akt/mTORC1 Axis by upregulating tribbles-3 pseudokinase. Clin Cancer Res. 2016;22:2508–19.

    Article  CAS  Google Scholar 

  14. Birtolo C, Go VL, Ptasznik A, Eibl G, Pandol SJ. Phosphatidylinositol 3-kinase: a link between inflammation and pancreatic cancer. Pancreas. 2016;45:21–31.

    Article  CAS  Google Scholar 

  15. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461–73.

    Article  CAS  Google Scholar 

  16. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126:1208–15.

    Article  Google Scholar 

  17. Ruess DA, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat Med. 2018;24:954–60.

    Article  CAS  Google Scholar 

  18. Dempke WCM, Uciechowski P, Fenchel K, Chevassut T. Targeting SHP-1, 2 and SHIP pathways: a novel strategy for cancer treatment? Oncology. 2018;95:257–69.

    Article  CAS  Google Scholar 

  19. Lianos GD, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360:114–8.

    Article  CAS  Google Scholar 

  20. Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology. 2015;15:S39–43.

    Article  CAS  Google Scholar 

  21. Huggett MT, et al. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget. 2016;7:18495–507.

    Article  Google Scholar 

  22. Moreau B, et al. Abstract 4484: BTP-114: an albumin binding cisplatin prodrug with improved and sustained tumor growth inhibition. Cancer Res. 2015;75:4484.

    Google Scholar 

  23. Ghosh C, et al. Abstract 1398: super-enhancers: possible target in pancreatic cancer for therapeutic approaches. Cancer Res. 2018;78:1398.

    Google Scholar 

  24. Rodela E, et al. Abstract LB-B27: Novel antitumor agent GZ17-6.02 exerts discrete effects on transcriptional regulation in pancreatic cancer cells and cancer associated fibroblasts. Mol Cancer Therap. 2018;17:LB–B27.

    Google Scholar 

  25. Kurth I, et al. Abstract 5863: RGX-202, a first-in-class small-molecule inhibitor of the creatine transporter SLC6a8, is a robust suppressor of cancer growth and metastatic progression. Cancer Res. 2018;78:5863.

    Google Scholar 

  26. van der Horst HJ, et al. Potent ex vivo anti-tumor activity in relapsed refractory multiple myeloma using novel DR5-specific antibodies with enhanced capacity to form hexamers upon target binding. Blood. 2017;130:1835.

    Google Scholar 

  27. Li A, et al. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology. 2014;146:1386–1396.e1–17.

    Article  CAS  Google Scholar 

  28. Bressy C, et al. LIF drives neural remodeling in pancreatic cancer and offers a new candidate biomarker. Cancer Res. 2018;78:909–21.

    Article  CAS  Google Scholar 

  29. Hingorani SR, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22:2848–54.

    Article  CAS  Google Scholar 

  30. Overman MJ, et al. Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). J Clin Oncol. 2018;36:4123.

    Article  Google Scholar 

  31. Wang W, et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34:757–774.e7.

    Article  CAS  Google Scholar 

  32. Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12:719–39.

    Article  Google Scholar 

  33. Dong C, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409:97–101.

    Article  CAS  Google Scholar 

  34. Beatty GL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–6.

    Article  CAS  Google Scholar 

  35. Singh SK, et al. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018;8:1323.

    Article  Google Scholar 

  36. Rodriguez-Garcia A, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015;21:1406–18.

    Article  CAS  Google Scholar 

  37. Abu-Yousif AO, et al. Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies. Mol Cancer Ther. 2018;17:B120.

    Article  Google Scholar 

  38. David JM, Fantini M, Annunziata CM, Arlen PM, Tsang KY. Abstract 3821: the neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway. Cancer Res. 2018;78:3821.

    Google Scholar 

  39. O’Reilly EM, et al. Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies. J Clin Oncol. 2017;35:4110.

    Article  Google Scholar 

  40. Loibner H, et al. Adoptive cellular immunotherapy with APN401, autologous cbl-b silenced peripheral blood mononuclear cells: data from a phase I study in patients with solid tumors. J Clin Oncol. 2018;36:3055.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Gastroenterology-Endocrinology-Nephrology-Nutrition and Metabolic Diseases, Ulm University Hospital, Ulm, Germany

    Thomas Seufferlein, Angelika Kestler, Alica Beutel, Lukas Perkhofer & Thomas Ettrich

Authors
  1. Thomas Seufferlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelika Kestler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alica Beutel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lukas Perkhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Ettrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Seufferlein .

Editor information

Editors and Affiliations

  1. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Christoph W. Michalski

  2. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jonas Rosendahl

  3. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Patrick Michl

  4. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jörg Kleeff

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Seufferlein, T., Kestler, A., Beutel, A., Perkhofer, L., Ettrich, T. (2020). Phase I Trials in Pancreatic Cancer. In: Michalski, C., Rosendahl, J., Michl, P., Kleeff, J. (eds) Translational Pancreatic Cancer Research. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-49476-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49476-6_15

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-49475-9

  • Online ISBN: 978-3-030-49476-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation